Patents by Inventor Reuven Bergman

Reuven Bergman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and methods for treating disorders associated with abnormal phosphate metabolism
    Patent number: 7682787
    Abstract: The present invention uncovers that mutations in GALNT3 gene encoding UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase (GalNAc-T3) cause familial tumoral calcinosis (FTC). Methods and pharmaceutical compositions useful for treating disorders associated with abnormal phosphate metabolism are provided. Specifically, inducers of GalNAc-T3 can be used to treat hyperphosphatemia related disorders such as FTC, and on the other hand, inhibitors of GalNAc-T3 can be used to treat disorders associated with hypophosphatemia, such as hypophosphatemic rickets.
    Type: Grant
    Filed: June 18, 2004
    Date of Patent: March 23, 2010
    Assignee: Technion Research & Development Foundation Ltd.
    Inventors: Eli Sprecher, Reuven Bergman
  • Compositions and Methods for Treating Disorders Associated with Abnormal Phosphate Metabolism
    Publication number: 20080206195
    Abstract: The present invention uncovers that mutations in GALNT3 gene encoding UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase (GalNAc-T3) cause familial tumoral calcinosis (FTC). Methods and pharmaceutical compositions useful for treating disorders associated with abnormal phosphate metabolism are provided. Specifically, inducers of GalNAc-T3 can be used to treat hyperphosphatemia related disorders such as FTC, and on the other hand, inhibitors of GalNAc-T3 can be used to treat disorders associated with hypophosphatemia, such as hypophosphatemic rickets. The present invention further provides methods and kits for diagnosing familial tumoral calcinosis as well as for identifying agents suitable for treating disorders associated with abnormal phosphate metabolism.
    Type: Application
    Filed: May 8, 2005
    Publication date: August 28, 2008
    Inventors: Eli Sprecher, Reuven Bergman
  • Compositions and methods for treating disorders associated with abnormal phosphate metabolism
    Publication number: 20050249718
    Abstract: The present invention uncovers that mutations in GALNT3 gene encoding UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase (GalNAc-T3) cause familial tumoral calcinosis (FTC). Methods and pharmaceutical compositions useful for treating disorders associated with abnormal phosphate metabolism are provided. Specifically, inducers of GalNAc-T3 can be used to treat hyperphosphatemia related disorders such as FTC, and on the other hand, inhibitors of GalNAc-T3 can be used to treat disorders associated with hypophosphatemia, such as hypophosphatemic rickets.
    Type: Application
    Filed: June 18, 2004
    Publication date: November 10, 2005
    Inventors: Eli Sprecher, Reuven Bergman
  • Methods of and compositions for modulating hair growth via P-cadherin modulators
    Publication number: 20040247555
    Abstract: A method of identifying a hair growth modulator (i.e., hair growth inhibitor or inducer) which comprises identifying a P-cadherin modulator (i.e., P-cadherin inhibitor or inducer); and testing whether the P-cadherin modulator is functional as a hair growth modulator.
    Type: Application
    Filed: October 6, 2003
    Publication date: December 9, 2004
    Inventors: Eli Sprecher, Reuven Bergman